Français
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
lymphoma/crise épileptique
Le lien est enregistré dans le presse-papiers
13 résultats
Low-dose Intra-arterial Bevacizumab for Edema and Radiation Necrosis Therapeutic Intervention (LIBERTI)
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
BACKGROUND Radiation Necrosis: Stereotactic radiosurgery has become integral in treatment of brain tumors and arteriovenous malformations (AVM). In up to 10% of cases, this can lead to radiation necrosis (RN) with significant surrounding vasogenic edema and mass effect. Medical treatment for RN
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
1. Introduction to investigational treatment(s) and other study treatment(s)
1.1 Overview of gemcitabine Gemcitabine (29,29-difluoro 29-deoxycytidine, dFdC) which developed from cytosine arabinoside (Ara-C) is an nucleoside analog used as chemotherapy. It was intended as an antiviral drug in
Rapid Infusion Rituximab, Hematologic, Oncologic, and Rheumatologic Disorders
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
The standard of care in patients receiving rituximab is to give the dose slowly and gradually increase the rate of rituximab until the full dose is given, which may take several hours. This is done in order to prevent a side effect of rituximab called an infusion reaction. Infusion reactions are
Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
PRIMARY OBJECTIVES:
I. To determine the feasibility of real-time therapeutic dose monitoring (TDM) for once daily intravenously (IV) busulfan administration as part of a preparative regimen for patients with lymphoma undergoing autologous stem cell transplantation.
SECONDARY OBJECTIVES:
I. To
Maintenance Lenalidomide in Lymphoma
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
Describe succinctly and clearly the past findings which justify the plan for this project. A summary of the relevant literature in the area of interest and reports of previous studies should be included.
For majority of lymphoma patients who relapse after complete response or who are primary
Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
Hematopoietic stem cell (HSC) transplantation, using human HLA-matched sibling or unrelated bone marrow or peripheral blood stem cell donor, has been used successfully to treat patients with high-risk or relapsed hematologic malignancies. However, use of this therapy has been limited by availability
Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide for Refractory or Relapsed Aggressive B-Cell Lymphomas
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
Fifty percent of patients with aggressive B cell non-Hodgkin lymphomas are expected to relapse after initial standard chemotherapy. There is no standard salvage regimen for patients with relapsed or refractory disease and at least 75% of patients are expected to succumb to their condition with the
Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
Phase I:
The Study Drugs:
Vorinostat is designed to cause chemical changes in different groups of proteins that are attached to DNA (the genetic material of cells), which may slow the growth of cancer cells or cause the cancer cells to die.
Erlotinib is designed to block the activity of a protein
Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
The Study Drugs:
Busulfan is designed to bind to DNA (the genetic material of cells), which may cause cancer cells to die.
Fludarabine is designed to make cancer cells less able to repair damaged DNA. This may increase the likelihood of the cells dying.
Cyclophosphamide is designed to interfere with
P-glycoprotein Inhibition as Adjunct Treatment for Medically Refractory Epilepsy.
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
The Center for Disease Control reports that epilepsy afflicts 2.7 million Americans with annual costs of $15.5 billion. They estimate that 3% of Americans will have a diagnosis of epilepsy by age 80, and decided in 1997 to focus on treatment, with a motto of "no seizures, no side
Phase II Trial of Pentostatin and Targeted Busulfan
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
Pentostatin (deoxycoformycin) is a purine analogue that is currently indicated for the treatment of chemo-naïve or interferon-refractory hairy cell leukemia. Pentostatin represents an ideal agent for conditioning recipients before allogeneic hematopoietic cell transplantation (HCT) due to its
a Phase II Study in Primary Central Nervous System Lymphoma
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
5 PATIENT SELECTION 5.1 Eligibility Criteria
Patients must fulfill all the following criteria to be eligible for admission for the study:
1. Histologically proven central nervous system lymphoma of brain parenchyma with or without leptomeningeal involvement.
2. No evidence of systemic lymphoma.
3.
A Pilot Study of the Use of Rituximab in the Treatment of Chronic Focal Encephalitis
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
Chronic Focal Encephalitis (Rasmussen's Encephalitis) is a condition characterized by a progressive hemiparesis, cognitive decline (including loss of language skills if the language dominant hemisphere is involved) and epileptic seizures that are typically refractory to medical treatment
La base de données d'herbes médicinales la plus complète soutenue par la science
- Fonctionne en 55 langues
- Cures à base de plantes soutenues par la science
- Reconnaissance des herbes par image
- Carte GPS interactive - étiquetez les herbes sur place (à venir)
- Lisez les publications scientifiques liées à votre recherche
- Rechercher les herbes médicinales par leurs effets
- Organisez vos intérêts et restez à jour avec les nouvelles recherches, essais cliniques et brevets
Tapez un symptôme ou une maladie et lisez des informations sur les herbes qui pourraient aider, tapez une herbe et voyez les maladies et symptômes contre lesquels elle est utilisée.
* Toutes les informations sont basées sur des recherches scientifiques publiées
